[go: up one dir, main page]

BRPI0808035A2 - uso de inibidores da degradação de p27, em particular argirina e derivados da mesma, para o tratamento de doenças proliferativas. - Google Patents

uso de inibidores da degradação de p27, em particular argirina e derivados da mesma, para o tratamento de doenças proliferativas.

Info

Publication number
BRPI0808035A2
BRPI0808035A2 BRPI0808035A BRPI0808035A BRPI0808035A2 BR PI0808035 A2 BRPI0808035 A2 BR PI0808035A2 BR PI0808035 A BRPI0808035 A BR PI0808035A BR PI0808035 A BRPI0808035 A BR PI0808035A BR PI0808035 A2 BRPI0808035 A2 BR PI0808035A2
Authority
BR
Brazil
Prior art keywords
argirine
derivatives
treatment
proliferative diseases
degradation inhibitors
Prior art date
Application number
BRPI0808035A
Other languages
English (en)
Inventor
Hinkelmann Bettina
Sasse Florenz
Steinmetz Heinrich
Nickeleit Irina
Malek Nisar
Frank Ronald
Original Assignee
Helmholtz-Zentrum für Infektionsforschung GmbH
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz-Zentrum für Infektionsforschung GmbH, Medizinische Hochschule Hannover filed Critical Helmholtz-Zentrum für Infektionsforschung GmbH
Publication of BRPI0808035A2 publication Critical patent/BRPI0808035A2/pt
Publication of BRPI0808035B1 publication Critical patent/BRPI0808035B1/pt
Publication of BRPI0808035B8 publication Critical patent/BRPI0808035B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04Dimeric indole alkaloids, e.g. vincaleucoblastine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0808035A 2007-02-28 2008-02-27 uso de inibidores da degradação de p27 para o tratamento de câncer BRPI0808035B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07004185A EP1964560A1 (en) 2007-02-28 2007-02-28 Use of inhibitors of the degradation of p27 for the treatment of cancer
EP07004185.0 2007-02-28
US96593207P 2007-08-22 2007-08-22
US60/965,932 2007-08-22
PCT/EP2008/001552 WO2008104387A1 (en) 2007-02-28 2008-02-27 Use of inhibitors of the degradation of p27, in particular argyrin and derivatives thereof, for the treatment of proliferative diseases

Publications (3)

Publication Number Publication Date
BRPI0808035A2 true BRPI0808035A2 (pt) 2017-05-02
BRPI0808035B1 BRPI0808035B1 (pt) 2020-11-17
BRPI0808035B8 BRPI0808035B8 (pt) 2021-05-25

Family

ID=38863411

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0808035A BRPI0808035B8 (pt) 2007-02-28 2008-02-27 uso de inibidores da degradação de p27 para o tratamento de câncer

Country Status (8)

Country Link
US (1) US8217071B2 (pt)
EP (2) EP1964560A1 (pt)
JP (1) JP5564267B2 (pt)
AU (1) AU2008220967B2 (pt)
BR (1) BRPI0808035B8 (pt)
CA (1) CA2679435C (pt)
ES (1) ES2396115T3 (pt)
WO (1) WO2008104387A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2138507A1 (en) 2008-06-23 2009-12-30 Helmholtz-Zentrum für Infektionsforschung GmbH Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
US8853249B2 (en) 2009-12-14 2014-10-07 Helmholtz-Zentrum für Infektionsforschungs GmbH Method for producing intermediates for the production of macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US20020123082A1 (en) * 2001-01-05 2002-09-05 Michele Pagano Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
GB2367553A (en) * 2000-09-04 2002-04-10 Novartis Ag Pharmaceutically Active Macrocycles
US20060035280A1 (en) * 2004-01-15 2006-02-16 Kuo-Sen Huang Screening methods for inhibitors of protein-protein binding interactions

Also Published As

Publication number Publication date
BRPI0808035B1 (pt) 2020-11-17
BRPI0808035B8 (pt) 2021-05-25
ES2396115T3 (es) 2013-02-19
AU2008220967A1 (en) 2008-09-04
US8217071B2 (en) 2012-07-10
US20100144822A1 (en) 2010-06-10
EP2120929A1 (en) 2009-11-25
JP2010519323A (ja) 2010-06-03
WO2008104387A1 (en) 2008-09-04
CA2679435A1 (en) 2008-09-04
JP5564267B2 (ja) 2014-07-30
AU2008220967B2 (en) 2013-03-21
EP2120929B1 (en) 2012-09-26
EP1964560A1 (en) 2008-09-03
CA2679435C (en) 2016-07-12

Similar Documents

Publication Publication Date Title
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0810523A2 (pt) Derivado heterocíclico de 5 membros e uso do mesmo para propósitos médicos.
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0810524A2 (pt) Derivado de (aza)indol e uso do mesmo para propósitos médicos
BRPI0813156A2 (pt) Haste intramedular com prendedor pivotante e método para uso da mesma
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
DK2049525T3 (da) N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf
BRPI0813828A2 (pt) Compostos antimicrobianos, a síntese dos mesmos e o uso dos mesmos para o tratamento de infecções em mamíferos
PT2109602E (pt) Derivados de tetraciclina para o tratamento de infecções bacterianas, virais e parasitárias
BRPI0722053A2 (pt) método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina
BRPI0810208A2 (pt) Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer.
BRPI0812944A2 (pt) Derivados de 6-(pirrolopiridinil)pirimidin-2-ilamina e o uso dos mesmos para o tratamento de câncer e aids
BRPI0914863A2 (pt) formulação tópica estável, e, uso da mesma
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0907572A2 (pt) Derivados de fluorglicosídeos aromáticos, fármacos compreendendo os referidos compostos e uso dos mesmos
BRPI0814529A2 (pt) Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central.
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
FR2915199B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BRPI0919794A2 (pt) dispositivo para uso intracorpóreo, e, composto
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.